Astrazeneca (AZN) Debt to Equity (2016 - 2025)
Astrazeneca (AZN) has 3 years of Debt to Equity data on record, last reported at $0.57 in Q4 2025.
- For Q4 2025, Debt to Equity fell 19.26% year-over-year to $0.57; the TTM value through Dec 2025 reached $0.57, down 19.26%, while the annual FY2025 figure was $0.57, 19.26% down from the prior year.
- Debt to Equity reached $0.57 in Q4 2025 per AZN's latest filing, down from $0.71 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.71 in Q4 2024 and bottomed at $0.57 in Q4 2025.
- Average Debt to Equity over 3 years is $0.66, with a median of $0.7 recorded in 2023.
- Peak YoY movement for Debt to Equity: rose 0.74% in 2024, then fell 19.26% in 2025.
- A 3-year view of Debt to Equity shows it stood at $0.7 in 2023, then increased by 0.74% to $0.71 in 2024, then fell by 19.26% to $0.57 in 2025.
- Per Business Quant database, its latest 3 readings for Debt to Equity were $0.57 in Q4 2025, $0.71 in Q4 2024, and $0.7 in Q4 2023.